| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0006-3223(99)00015-3 |
| P698 | PubMed publication ID | 10472414 |
| P2093 | author name string | Soares JC | |
| Innis RB | |||
| P2860 | cites work | Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects | Q22248075 |
| Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter | Q24310836 | ||
| Dopamine D4 receptors elevated in schizophrenia | Q24318936 | ||
| Molecular pathology of schizophrenia: more than one disease process? | Q24676503 | ||
| Statistical parametric maps in functional imaging: A general linear approach | Q27864122 | ||
| Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport | Q28301517 | ||
| Implications of normal brain development for the pathogenesis of schizophrenia | Q29618740 | ||
| Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses | Q29618915 | ||
| Structural brain imaging in schizophrenia: a selective review | Q30581145 | ||
| Increased dopamine transmission in schizophrenia: relationship to illness phases | Q33679807 | ||
| Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease | Q33914552 | ||
| Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs | Q34192438 | ||
| Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. | Q48854560 | ||
| 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. | Q48880389 | ||
| Decreased frontal cortical serotonin2A receptors in schizophrenia. | Q48915737 | ||
| Striatal dopamine D2 receptor quantification and superior temporal gyrus: volume determination in 14 chronic schizophrenic subjects. | Q48959932 | ||
| Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. | Q49065165 | ||
| Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. | Q49119845 | ||
| Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. | Q51017600 | ||
| [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. | Q51823312 | ||
| Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. | Q51994574 | ||
| Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. | Q52021168 | ||
| Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. | Q52033175 | ||
| Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. | Q52051956 | ||
| 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. | Q52055580 | ||
| Metabolism of alpha-methyltyrosine in man: relationship to its potency as an inhibitor of catecholamine biosynthesis | Q34272903 | ||
| Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride | Q34298626 | ||
| Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer | Q34301516 | ||
| Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates | Q34342995 | ||
| Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain | Q34363450 | ||
| Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo | Q34366904 | ||
| 18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors. | Q34392904 | ||
| Dopamine D2-like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline | Q34415539 | ||
| Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. | Q34488059 | ||
| EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. | Q34540614 | ||
| Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics | Q34559171 | ||
| Provocative tests with psychostimulant drugs in schizophrenia | Q34559517 | ||
| Dopamine in schizophrenia: a review and reconceptualization | Q34568816 | ||
| Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia | Q34707093 | ||
| Glutamate receptor dysfunction and schizophrenia | Q34719075 | ||
| A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex | Q35229075 | ||
| Elevated dopa decarboxylase activity in living brain of patients with psychosis | Q35927690 | ||
| Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method | Q36050571 | ||
| In vivo 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling | Q36055611 | ||
| Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy | Q36185748 | ||
| Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia | Q36500321 | ||
| Metabolite concentrations in the developing brain estimated with proton MR spectroscopy | Q36728973 | ||
| Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. | Q38755328 | ||
| Dopaminergic mechanisms in schizophrenia: The antipsychotic effect and the disease process | Q39209529 | ||
| Neurotransmitter Receptors in Frontal Cortex of Schizophrenics | Q39261348 | ||
| Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses | Q39463580 | ||
| Dopamine receptors and the dopamine hypothesis of schizophrenia | Q39471744 | ||
| Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum | Q39488987 | ||
| Increased dopamine-receptor sensitivity in schizophrenia | Q39498162 | ||
| Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients | Q39533948 | ||
| The role of serotonin in schizophrenia | Q39547186 | ||
| The current status of the dopamine hypothesis of schizophrenia | Q39577491 | ||
| Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia | Q40576763 | ||
| Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: preliminary studies | Q40870201 | ||
| Serotonin-dopamine interaction and its relevance to schizophrenia | Q40945989 | ||
| Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. | Q52506986 | ||
| Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. | Q54624708 | ||
| Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia | Q57004378 | ||
| Reversible decreases in N-acetylaspartate after acute brain injury | Q57043105 | ||
| Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635 | Q57535487 | ||
| SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain | Q57781112 | ||
| Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia | Q57839317 | ||
| Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats | Q59076248 | ||
| [3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia | Q61714004 | ||
| Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia | Q62601732 | ||
| Synaptic Concentration of Dopamine in the Mouse Striatum in Relationship to the Kinetic Properties of the Dopamine Receptors and Uptake Mechanism | Q67897341 | ||
| High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors | Q67901608 | ||
| Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients | Q68310985 | ||
| Studies in postmortem dopamine uptake. II. Alterations of the synaptosomal catecholamine uptake in postmortem brain regions in schizophrenia | Q68965633 | ||
| [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics | Q70158501 | ||
| Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride | Q71302739 | ||
| Quantitative 1H spectroscopic imaging of human brain at 4.1 T using image segmentation | Q71507277 | ||
| 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors | Q71564942 | ||
| An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy | Q72181807 | ||
| Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia | Q72222106 | ||
| Abnormal frontal lobe phosphorous metabolism in bipolar disorder | Q72248816 | ||
| Proton magnetic resonance spectroscopy (1H MRS) of the hippocampal formation in schizophrenia: a pilot study | Q72367731 | ||
| Tritiated LSD Binding in Frontal Cortex in Schizophrenia | Q72461766 | ||
| Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis | Q72565124 | ||
| Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone | Q72676838 | ||
| Evaluation of 5-[18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors | Q72700433 | ||
| 31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia | Q41095454 | ||
| D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride | Q41173321 | ||
| Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites | Q41199393 | ||
| The role of serotonin in the pathophysiology and treatment of schizophrenia | Q41337912 | ||
| Abnormal excitatory neurotransmitter metabolism in schizophrenic brains | Q41670269 | ||
| Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons | Q41827725 | ||
| Initial investigation of the left temporoparietal region in schizophrenia by 31P magnetic resonance spectroscopy | Q41965538 | ||
| Dopamine D2 receptor dimers and receptor-blocking peptides | Q42063592 | ||
| Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics | Q44239783 | ||
| Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging | Q44666779 | ||
| D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory | Q45191426 | ||
| Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain | Q45248583 | ||
| Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases | Q45297058 | ||
| Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. | Q45306324 | ||
| Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride | Q45395570 | ||
| Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy | Q46634117 | ||
| Quantification of neuroreceptors in the living human brain: III. D2-like dopamine receptors: theory, validation, and changes during normal aging | Q46775657 | ||
| D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene | Q47806940 | ||
| No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. | Q47951473 | ||
| Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains | Q48166703 | ||
| Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography | Q48186320 | ||
| The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research | Q48186899 | ||
| D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study | Q48207608 | ||
| Human brain dopamine receptors in children and aging adults | Q48236020 | ||
| Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia | Q48236425 | ||
| A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls | Q48247760 | ||
| Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics | Q48269596 | ||
| Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia | Q48283671 | ||
| Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride | Q48301941 | ||
| Reduced [3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses? | Q48342515 | ||
| Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. | Q48378899 | ||
| Dopamine D2 densities and the schizophrenic brain. | Q48404440 | ||
| Visualization of extrastriatal dopamine D2 receptors in the human brain. | Q48407407 | ||
| The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography | Q48427569 | ||
| Evidence for striatal dopamine release during a video game. | Q48458659 | ||
| [carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo. | Q48460718 | ||
| Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics | Q48521493 | ||
| Altered development of prefrontal neurons in rhesus monkeys with neonatal mesial temporo-limbic lesions: a proton magnetic resonance spectroscopic imaging study. | Q48572568 | ||
| Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. | Q48614993 | ||
| Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. | Q48622012 | ||
| Imaging D2 receptor occupancy by endogenous dopamine in humans. | Q48632608 | ||
| Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. | Q48638366 | ||
| Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. | Q48669559 | ||
| Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. | Q48712833 | ||
| Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography. | Q48721313 | ||
| Amphetamine induced decreases in (18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET). | Q48745145 | ||
| Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. | Q48777045 | ||
| Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. | Q48800661 | ||
| Presynaptic dopaminergic function in the striatum of schizophrenic patients. | Q48802317 | ||
| Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. | Q48823706 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 600-615 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Biological Psychiatry | Q4914961 |
| P1476 | title | Neurochemical brain imaging investigations of schizophrenia | |
| P478 | volume | 46 |
| Q30690611 | Can brain-imaging studies provide a 'mood stabilizer signature?'. |
| Q37415050 | Could stress cause psychosis in individuals vulnerable to schizophrenia? |
| Q43623884 | Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls |
| Q41703569 | Disruptions of Sleep/Wake Patterns in the Stable Tubule Only Polypeptide (STOP) Null Mouse Model of Schizophrenia |
| Q51413531 | Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. |
| Q44659275 | Dopamine transporter change in drug-naı̈ve schizophrenia: an imaging study with 99mTc-TRODAT-1 |
| Q64078147 | Effects of Amisulpride Adjunctive Therapy on Working Memory and Brain Metabolism in the Frontal Cortex of Patients with Schizophrenia: A Preliminary Positron Emission Tomography/Computerized Tomography Investigation |
| Q35084965 | Evolutionary perspectives on schizophrenia |
| Q34574575 | Functional brain mapping of psychopathology. |
| Q46211520 | Functional connectivity and working memory in schizophrenia: an EEG study |
| Q97560369 | Imaging of Monoamine Neurotransmitters with Fluorescent Nanoscale Sensors |
| Q30854782 | Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation |
| Q37497379 | Improving antidepressant drugs: update on recently patented compounds |
| Q97884855 | Label-free imaging of neurotransmitters in live brain tissue by multi-photon ultraviolet microscopy |
| Q44140651 | PET in neurology and psychiatry I. PET with FDG in the study of the CNS |
| Q38578521 | Postmortem studies in schizophrenia. |
| Q40589475 | Predicting EEG responses using MEG sources in superior temporal gyrus reveals source asynchrony in patients with schizophrenia |
| Q46571111 | Processing efficiency of a verbal working memory system is modulated by amphetamine: an fMRI investigation |
| Q30949960 | Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology |
| Q44112647 | Proton magnetic resonance spectroscopy of the inferior frontal gyrus and thalamus and its relationship to verbal learning task performance in patients with schizophrenia: a preliminary report |
| Q33335176 | Reduction of latent inhibition by D-amphetamine in a conditioned suppression paradigm in humans |
| Q43577897 | Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and. |
| Q34411673 | Rethinking models of psychotropic drug action |
| Q56813382 | Signal Transduction and Genes-to-Behaviors Pathways in Psychiatric Diseases |
| Q28182063 | Signal transduction and genes-to-behaviors pathways in psychiatric diseases |
| Q44660004 | Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study |
| Q38056122 | The biochemical womb of schizophrenia: A review |
Search more.